Article thumbnail

Taxanes in the Adjuvant Treatment of Breast Cancer: Why Not Yet?

By Martine J. Piccart, Caroline Lohrisch, Luc Duchateau and Marc Buyse

Abstract

The taxanes paclitaxel and docetaxel represent the most ac-tive chemotherapeutic agents developed for the treatment of advanced breast cancer in the last decade, and they are now being incorporated into adjuvant chemotherapy trials for lymph node-positive breast cancer with the hope of improv-ing on the results achieved with CMF (cyclophosphamide, methotrexate, 5-fluorouracil) or anthracycline-based regi-mens. So far, three randomized paclitaxel-based adjuvant clinical trials enrolling 3170 women (Cancer and Leukemi

Year: 2015
OAI identifier: oai:CiteSeerX.psu:10.1.1.541.5112
Provided by: CiteSeerX
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://jncimono.oxfordjournals... (external link)
  • http://jncimono.oxfordjournals... (external link)
  • http://citeseerx.ist.psu.edu/v... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.